**ANNOUNCEMENTS IN CONJUNCTION WITH
THERATECHNOLOGIES ANNUAL MEETING**

Montreal, Canada – May 20, 2015 - Theratechnologies Inc. (TSX: TH) today held its annual meeting of shareholders, chaired by Dawn Svoronos, chair of the board of Theratechnologies.

During the meeting, management reviewed last year's financial and corporate highlights. It also discussed the Company's perspectives for the future.

"Last year most definitely marked a significant milestone in Theratechnologies' history. Regaining rights to *EGRIFTA™* (tesamorelin for injection) in the United States is the spearhead of a most promising approach on which we have based our growth and profitability business model. During the next year, our priority will be to sustain efforts in that territory while preparing for the Canadian launch," said Luc Tanguay, President and CEO, Theratechnologies Inc.

As part of the meeting, the following people were elected as directors of the Company by a majority of the votes.

	IN FAVOUR	% IN FAVOUR	ABSENTION	% ABSTENTION
Gérald A. Lacoste	19,151,474	99.60	76,862	0.40
David Lilley	19,149,304	99.59	79,032	0.41
Paul Pommier	19,149,674	99.59	78,662	0.41
Dawn Svoronos	19,179,084	99.74	49,252	0.26
Jean-Denis Talon	19,148,974	99.59	79,362	0.41
Luc Tanguay	19,177,754	99.74	50,582	0.26

This represents the first mandate for David Lilley as board member of Theratechnologies.

"David's impressive track record in the pharmaceutical sector will certainly be most useful to our company and I take this opportunity to welcome him. His expertise is very timely as Theratechnologies enters a new phase of its existence," said Dawn Svoronos, Chair of the Board, Theratechnologies Inc.

At the meeting, KPMG was appointed as auditors of the Company.

About Theratechnologies

Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and improved quality of life.

Forward-Looking Information

-30-

Information:
Denis Boucher
514-913-1957